Description
Novartis brolucizumab (RTH258) demonstrates superiority versus aflibercept in key secondary endpoint measures of disease activity in nAMD, a leading cause of blindness.
Usage Rights & Restrictions
This media asset is free for editorial broadcast, print, online and radio use. It is restricted for other purposes.